glp 1 triple agonist Beyond GLP-1: Retatrutide's triple-agonist mechanism (GLP-1, GIP, glucagon) is redefining metabolic health. Phase 2 data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based protocols demand nutrition support alongside prescribing A review of an investigational

2), with the complete dataset cataloged in Supplementary Table 4

2023;24:5441 Hulimane Shivaswamy R, Binulal P, Benoy A, Lakshmiramanan K, Bhaskar N, Pandya HJ

Take the First Step in Knowing if Weight Loss Surgery is Right for You Real People, Real Results Hear How Weight Loss Surgery Changed Their Lives You May Also Like Make an informed, confident decision about surgery by understanding your options, risks, recovery, and whether a non-surgical path may be right for you

Back Sheridan, C (14 April 2025) 'Not just obesity: GLP-1 receptor agonists advance on addiction', Nature Biotechnology , 43, 455-47.Back Sims, EK, Carr, ALJ, Oram, RA, et al (15 July 2022) '100 years of insulin: celebrating the past, present and future of diabetes therapy', Nature Medicine , 27/7, 1154-64